A Phase 1 interventional study of Bicalutamide implant in Prostate Adenocarcinoma and Lower Urinary Tract Symptoms, sponsored by Alessa Therapeutics Inc.. Completed at 4 sites in 3 countries. Open to male participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by Alessa Therapeutics Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lower Urinary Tract Symptoms with a site in Australia — 1 open to participants now, 4 under way, none of them phase 3. Lower Urinary Tract Symptoms · Australia.
Among the 10 studies in Lower Urinary Tract Symptoms with a site in Australia, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 5th registered.
417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
Browse Lower Urinary Tract Symptoms studies →1 of the 10 studies in Lower Urinary Tract Symptoms with a site in Australia is open now. Recruiting first, the newest first:
RDC Clinical Pty Ltd · Sites in Australia
Ages 40+ · Men only · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 35 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 100 across 272 interventional studies indexed under Lower Urinary Tract Symptoms.
Median enrollment 122 across the 10 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 8 most frequent:
Alessa Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Alessa Therapeutics Inc. has 1 study filed under Lower Urinary Tract Symptoms — fewer than ten, so there is no comparison to draw.
1 of the studies in Lower Urinary Tract Symptoms with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07816172RDC Clinical Pty LtdEffects of Macanity on Urinary Health in Males With Lower Urinary Tract Symptoms | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lower Urinary Tract Symptoms with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.
This prospective, multi-center, single-arm feasibility study is planned to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate in patients presenting for treatment of prostate cancer. Study participants will have placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
Combination Product: Bicalutamide implant
Biolen bicalutamide implant
Safety as measured by number and incidence of adverse events
Adverse Events
Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation
change in prostate size
prostate measurement by MRI
Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation
change in tumor size
tumor measurement by MRI
Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation
change in Prostate Specific Antigen (PSA)
PSA level
Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in May 2023, 30 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide
Lower Urinary Tract Symptoms →